Last BACE bombs: Eisai, Biogen give up on elenbecestatThe final BACE inhibitor in clinical testing for Alzheimer’s disease – Eisai and Biogen’s elenbecestat – has been Share XLast BACE bombs: Eisai, Biogen give up on elenbecestathttps://pharmaphorum.com/news/last-bace-bombs-eisai-biogen-give-up-on-elenbecestat/
Merck’s failure casts gloom over remaining BACE Alzheimer’s drugsBut trial in patients in early stage of the disease continues. Share XMerck’s failure casts gloom over remaining BACE Alzheimer’s drugshttps://pharmaphorum.com/news/merck-co-halts-alzheimers-trial/